ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1104

Pathogenic UBA1 Variants in Japanese Patients with Relapsing Polychondritis

Naomi Tsuchida1, Yosuke Kunishita2, Yuri Uchiyama1, Yohei Kirino3, Kaoru Takase-Minegishi1, Ryusuke Yoshimi1, Hideaki Nakajima1 and Naomichi Matsumoto1, 1Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, 3Yokohama City University, Yokohama, Japan

Meeting: ACR Convergence 2021

Keywords: Autoinflammatory diseases, relapsing polychondritis, UBA1, VEXAS syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Pathogenic somatic variants in the ubiquitin like modifier activating enzyme 1 gene (UBA1) were discovered in individuals with systemic inflammation of cartilage, skin, and blood vessels accompanied by hematological abnormalities, named VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, affecting only male patients. Some patients with VEXAS were reported to have a relapsing polychondritis (RP) phenotype. To determine clinical and genetic features of individuals with RP likely caused by pathogenic somatic variants in UBA1.

Methods: Fourteen patients with RP who met the Damiani and Levine classification criteria were recruited (12 men, 2 women; median onset age [interquartile range] 72.1 years [67.1–78.0]). Sanger sequencing of UBA1 was performed using genomic DNA from peripheral blood leukocytes or bone marrow tissue. Droplet digital PCR (ddPCR) and peptide nucleic acid (PNA)-clamping PCR were used to detect low-prevalence somatic variants. Clinical features of the patients were investigated retrospectively. Clinical features were compared pathogenic UBA1 variant-positive and negative patients. Categorical variables were analyzed using the chi-square test and exact unconditional z-pooled test. Continuous variables were examined using the Mann–Whitney U test. A p-value < 0.0028 (= 0.05/18) was considered statistically significant using Bonferroni’s corrected p-value for multiple testing (N=18).

Results: UBA1 was examined in 13 of the 14 patients; 73% (8/11) of the male patients had somatic UBA1 variants (c.121A >C, c.121A >G, or c.122T >C resulting in p.Met41Leu, p.Met41Val, or p.Met41Thr, respectively). All the variant-positive patients had systemic symptoms, including a significantly high prevalence of skin lesions. ddPCR detected low-prevalence (0.14%) of somatic variant (c.121A >C) in one female patient, which was subsequently confirmed by PNA-clamping PCR.

Conclusion: Genetic screening for pathogenic UBA1 variants should be considered in patients with RP, especially male patients with skin lesions.

Table. Clinical features of the 14 patients with relapsing polychondritis and UBA1 variants detected by Sanger sequencing


Disclosures: N. Tsuchida, None; Y. Kunishita, None; Y. Uchiyama, None; Y. Kirino, Chugai, 5, Ono, 5; K. Takase-Minegishi, None; R. Yoshimi, None; H. Nakajima, None; N. Matsumoto, None.

To cite this abstract in AMA style:

Tsuchida N, Kunishita Y, Uchiyama Y, Kirino Y, Takase-Minegishi K, Yoshimi R, Nakajima H, Matsumoto N. Pathogenic UBA1 Variants in Japanese Patients with Relapsing Polychondritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/pathogenic-uba1-variants-in-japanese-patients-with-relapsing-polychondritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pathogenic-uba1-variants-in-japanese-patients-with-relapsing-polychondritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology